160 related articles for article (PubMed ID: 9067264)
1. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique.
Huang TH; Laux DE; Hamlin BC; Tran P; Tran H; Lubahn DB
Cancer Res; 1997 Mar; 57(6):1030-4. PubMed ID: 9067264
[TBL] [Abstract][Full Text] [Related]
2. [Effect of aberrant DNA methylation on the expression of cancer-related genes in Cd-transformed cells].
Lei YX; Joseph P; Wu ZL; Ong TM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2003 Apr; 21(2):114-6. PubMed ID: 14761530
[TBL] [Abstract][Full Text] [Related]
3. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
4. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
6. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
8. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR.
Gebhard C; Schwarzfischer L; Pham TH; Andreesen R; Mackensen A; Rehli M
Nucleic Acids Res; 2006 Jul; 34(11):e82. PubMed ID: 16822855
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation differences associated with tumor tissues identified by genome scanning analysis.
Liang G; Salem CE; Yu MC; Nguyen HD; Gonzales FA; Nguyen TT; Nichols PW; Jones PA
Genomics; 1998 Nov; 53(3):260-8. PubMed ID: 9799591
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR.
Gonzalgo ML; Liang G; Spruck CH; Zingg JM; Rideout WM; Jones PA
Cancer Res; 1997 Feb; 57(4):594-9. PubMed ID: 9044832
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S
Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
13. Mapping of ER gene CpG island methylation-specific polymerase chain reaction.
Lapidus RG; Nass SJ; Butash KA; Parl FF; Weitzman SA; Graff JG; Herman JG; Davidson NE
Cancer Res; 1998 Jun; 58(12):2515-9. PubMed ID: 9635570
[TBL] [Abstract][Full Text] [Related]
14. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
Ueki T; Walter KM; Skinner H; Jaffee E; Hruban RH; Goggins M
Oncogene; 2002 Mar; 21(13):2114-7. PubMed ID: 11960385
[TBL] [Abstract][Full Text] [Related]
15. [Aberrant methylation of APC and Bikunin CpG islands in sporadic breast carcinomas].
Chen YL; Xie YT; Wen XZ; Deng DJ
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():17-9. PubMed ID: 17767851
[TBL] [Abstract][Full Text] [Related]
16. Denaturing high-performance liquid chromatography (DHPLC) as a reliable high-throughput prescreening method for aberrant promoter methylation in cancer.
Betz B; Florl AR; Seifert HH; Dall P; Schulz WA; Niederacher D
Hum Mutat; 2004 Jun; 23(6):612-20. PubMed ID: 15146466
[TBL] [Abstract][Full Text] [Related]
17. Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells.
Tryndyak V; Kovalchuk O; Pogribny IP
Anal Biochem; 2006 Sep; 356(2):202-7. PubMed ID: 16824473
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
19. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
20. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
